If this option is selected, the repeat endoscopy is usually performed every 6 months in the first year, and then every year after that
(2012) demonstrated: Statistically significant reductions in visceral adipose tissue of approximately 1518% over 26 weeks compared to placebo Meaningful increases in IGF-1 levels Improvements in triglyceride profiles in some patient subgroups Effects were partially reversed upon discontinuation, suggesting that sustained benefit requires ongoing therapy The consistency of the VAT reduction finding across multiple trials is what anchors tesamorelin's clinical utility
Pu, S.-Y., et al
Future trials should monitor not only benefits but also potential risks, such as microbiome imbalance, over-colonization, or antibiotic resistance gene transfer
Study Shows Simple Blood Test Could Detect Liver Injury Earlier By: Amanda Siegfried | March 5, 2021 University of Texas at Dallas chemist Dr
17/029832, 17/218408 and 17/164736, respectively)